MedTrace Logo

Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

NCT00744081 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2023-03-10

No results posted yet for this study

Summary

The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.

Conditions

Interventions

DRUG

Glivec

DRUG

Mitoxantrone

DRUG

Topotecan

DRUG

AraC

Sponsors & Collaborators

  • Goethe University

    lead OTHER

Principal Investigators

  • Lothar Bergmann, MD, PhD · University Hospital of Frankfurt, Medical Dept. II

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00744081 on ClinicalTrials.gov